The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...

May 11, 2025 · In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum …

With a 2023 Journal Impact Factor of 96.2, NEJM is a top-ranked, global, multi-specialty journal in the general medicine category. [Source: 2023 Journal Impact Factor, Journal Citation Reports ...

Explore the current issue of The New England Journal of Medicine (Vol. 392 No. 23).

The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care.

Jun 1, 2025 · Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) …

3 days ago · Explore this issue of The New England Journal of Medicine (Vol. 0 No. 0).

Jun 1, 2025 · Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence is lacking. In this phase 3, randomized trial …

Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell …

May 30, 2025 · First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF …